Optimization of Luminescent Assay for Screening of Cyclin-Dependent Kinase 2 Inhibitors

被引:2
|
作者
Suthar, M. P. [1 ]
Patel, M. M. [2 ]
机构
[1] Ganpat Univ, Shree SK Patel Coll Pharmaceut Educ & Res, Dept Biotechnol, Kherva 382711, India
[2] Kalol Inst Pharm, Kalol 382721, India
关键词
Cyclin-dependent kinase 2; histone H1; luminescence; assay; optimization; PROTEIN-KINASES;
D O I
10.4103/0250-474X.70472
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cyclin-dependent kinases are most extensively studied targets for cancer chemotherapy since the tumor cells exhibit false checkpoints and can proliferate even if the genome is compromised. Cyclin-dependent kinases ensure the tight regulation of the cell cycle execution by mediating phosphorylation of cellular proteins. Deregulation of the cyclin-dependent kinase 2 activity by cellular and external factors leads to many diseases like cancers. Different methods like radiolabeled, fluorescence and luminescence are available for screening of library of compounds against kinases. However, bioluminescent methods offer several advantages like low background and no effect of fluorescent compound interference. Present study is focused on development, optimization and validation of cyclin-dependent kinase 2 assay which is suitable for identification potent and selective, ATP competitive and non-competitive inhibitors of cyclin-dependent kinase 2. The aim of present investigation was to optimize the assay for cyclin-dependent kinase 2/cylin A and cyclin-dependent kinase 2/cyclin E with use of bioluminescence based biochemical reaction. Both cyclin-dependent kinase 2 which are cyclin-dependent kinase 2/cyclin A and cyclin-dependent kinase 2/cyclin E complexes, have different affinity for ATP. Therefore, both isoform analogs of cyclin-dependent kinase 2 were optimized separately. Optimum cyclin-dependent kinase 2/cyclin A and cyclin-dependent kinase 2/cyclin E concentration were found to be 250 ng/well and 200 ng/well, respectively. Optimum substrate (histone H1) concentration was found to be 2.5 mg/ml for both cyclin-dependent kinase 2 analogs. Optimum reaction time was found to be 20 min for both cyclin-dependent kinase 2/cyclin complexes.
引用
收藏
页码:290 / 294
页数:5
相关论文
共 50 条
  • [21] Cyclin-dependent kinase inhibitors: The age of crystals
    Pines, J
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 1997, 1332 (01): : M39 - M42
  • [22] Cyclin-dependent kinase inhibitors and human cancer
    Kamb, A
    CYCLIN DEPENDENT KINASE (CDK) INHIBITORS, 1998, 227 : 139 - 148
  • [23] Optimization of norbornyl-based carbocyclic nucleoside analogs as cyclin-dependent kinase 2 inhibitors
    Kopruluoglu, Cemal
    Dejmek, Milan
    Sala, Michal
    Ajani, Haresh
    Hrebabecky, Hubert
    Fanfrlik, Jindrich
    Jorda, Radek
    Dracinsky, Martin
    Prochazkova, Eliska
    Sacha, Pavel
    Krystof, Vladimir
    Hobza, Pavel
    Lepsik, Martin
    Nencka, Radim
    JOURNAL OF MOLECULAR RECOGNITION, 2020, 33 (08)
  • [24] Cyclins, cyclin-dependent kinases, cyclin-dependent kinase inhibitors and their role in head and neck cancer
    Jeannon, JP
    Wilson, JA
    CLINICAL OTOLARYNGOLOGY, 1998, 23 (05): : 420 - 424
  • [25] Novel potent indolinone inhibitors of cyclin-dependent kinase 2.
    Huang, P
    Shirazian, SH
    Rice, A
    Flocco, M
    Casale, E
    Wei, J
    Tang, C
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2003, 225 : U186 - U186
  • [26] Emerging drug profile: cyclin-dependent kinase inhibitors
    Blachly, James S.
    Byrd, John C.
    LEUKEMIA & LYMPHOMA, 2013, 54 (10) : 2133 - 2143
  • [27] Advances in cyclin-dependent kinase inhibitors for the treatment of melanoma
    Julve, Maximilian
    Clark, James J.
    Lythgoe, Mark P.
    EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (03) : 351 - 361
  • [28] Cyclin-Dependent Kinase Inhibitors and the Treatment of Gastrointestinal Cancers
    Mikhail, Sameh
    Albanese, Christopher
    Pishvaian, Michael J.
    AMERICAN JOURNAL OF PATHOLOGY, 2015, 185 (05): : 1185 - 1197
  • [29] Discovery and Development of Cyclin-Dependent Kinase 8 Inhibitors
    Lv, Xiao
    Tian, Yongbing
    Li, Shiyu
    Cheng, Kai
    Huang, Xufeng
    Kong, Haiyan
    Liao, Chenzhong
    Xie, Zhouling
    CURRENT MEDICINAL CHEMISTRY, 2020, 27 (32) : 5429 - 5443
  • [30] Substituted aminobenzimidazole pyrimidines as cyclin-dependent kinase inhibitors
    Verma, S
    Nagarathnam, D
    Shao, JX
    Zhang, L
    Zhao, J
    Wang, YM
    Li, TD
    Mull, E
    Enyedy, I
    Wang, CG
    Zhu, QM
    Altieri, M
    Jordan, J
    Dang, TTA
    Reddy, S
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (08) : 1973 - 1977